期刊文献+

阿托伐他汀钙对实验性脑缺血再灌注后炎症反应的影响 被引量:14

Effects of Atorvastatin on Inflammatory Response of Cerebral Ischemia—Reperfusion Injury in Rats
下载PDF
导出
摘要 目的研究阿托伐他汀钙对大鼠大脑中动脉缺血再灌注后脑组织中核因子κBp56、细胞间粘附分子1蛋白表达及炎症细胞渗出的影响。方法采用大脑中动脉线栓法制备局灶性脑缺血再灌注模型,参考Longa5分制法在动物麻醉清醒后进行评分,应用免疫组织化学检测核因子κBp56和细胞间粘附分子1蛋白表达,运用HE染色观察多形核白细胞浸润的情况。结果他汀组与缺血组比较,大鼠缺血侧脑组织中核因子κBp56蛋白和细胞间粘附分子1蛋白表达减少(P<0.05),多形核白细胞渗出减少(P<0.05),神经病学评分也减少(P<0.05)。结论阿托伐他汀钙能抑制缺血再灌注后脑组织中核因子κBp56和细胞间粘附分子1蛋白表达,从而减少炎症细胞渗出,抑制大鼠实验性脑缺血再灌注后炎症反应,最终减轻其缺血再灌注损伤。 Aim To investigate ff the atorvastatin calcium protects the brain against injury induced by ischemia/reperfusion( I/R) and its impact on the expression of nuclear factor-tcBp56(NF-κBp56) and intercellular adhesion molecule- 1 (ICAM-1 ). Methods Rats were subjected to cerebral I/R injury through the occlusion of the middle cerebral artery. Neurological deficits were determined by Longa's score. The expression of ICAM-1 and NF-κB were detected by immuno-histochemical analysis. The effusion of polymorphonuclear leucocytes (PMNLs) in brain tissue was evaluated by HE staining. Results In group I/R + stalin, contrasting to group I/R, the expression of ICAM-1 and NF-κB were decreased significantly ( P 〈 0.05) ; the Longa's score were lower ( P 〈 0.05 ) ; and the effusion of PMNLs were inhibited ( P 〈 0.05 ). Conclusion Atorvastatincalcium has protective effects on the brain after experimental stroke and its probable mechanism involves the decreased expression of NF-κBp56 and ICAM-1.
出处 《中国动脉硬化杂志》 CAS CSCD 2007年第1期40-42,共3页 Chinese Journal of Arteriosclerosis
基金 湖南省自然科学基金(02JJY3028) 湖南省卫生厅课题(B2005023)
关键词 神经病学 脑缺血再灌注 阿托伐他汀钙 炎症反应 多形核白细胞 核因子KBp56 细胞间 粘附分子1 Ischemia/Reperfusion Atorvastafin-Calcium Inflammatory Polymorphonuelear Leucocytes Nuclear Factor-κBp56 Intercellular Adhesion Molecule-1
  • 相关文献

参考文献10

  • 1董少红,温隽珉,罗林杰,陈科奇,梁新剑,李宜富,刘华东,陈焕展,黄志昕.大剂量阿托伐他汀对急性冠状动脉综合征的调脂及抗炎作用[J].中国动脉硬化杂志,2006,14(7):613-616. 被引量:15
  • 2Gu W,Zhao H,Yenari MA,Sapolsky RM,Steinberg GK.Catalase over-expression protects striatal neurons from transient focal cerebral ischemia[J].Neuroreport,2004,15(3):413-416.
  • 3Longa EZ,Weinstein PR,Carlson S,Cummins R.Reversible middle cerebral artery occlusion without craniectomy in rats[J].Stroke,1989,20(1):84 291.
  • 4Han HS,Yenari MA.Cellular targets of brain inflammation in stroke[J].Curr Opin Investig Drugs,2003,4(5):522-529.
  • 5Berti R,Williams AJ,Moffett JR,Hale SL,Velarde LC,Elliott PJ.Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury[J].J Cereb Blood Flow Metab,2002,22 (9):1 068-079.
  • 6Ghosh S,Karin M.Missing pieces in the NF-kappa B puzzle[J].Cell,2002,109 (Suppl):S81-S96.
  • 7Madonna R,Di Napoli P,Massaro M,Grilli A,Felaco M,De Caterina A,et al.Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts[J].J Biol Chem,2005,280 (14):13 503-511.
  • 8Hernandez-Presa MA,Martin-Ventura JL,Ortego M,Gomez-Hernandez A,Tunon J,Hernandez-Vargas P,et al.Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cell[J].Atherosclerosis,2002,160 (1):49-58.
  • 9Landsberger M,Wolff B,Jantzen F,Rosenstenqel C,Voqelqesang D,Staudt A,et al.Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cell[J].Atherosclerosis,2007,190 (1):43-52.
  • 10Kleemann R,Kooistra T.HMG-CoA reductase inhibitors:effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol[J].Curr Drug Targets Cardiovasc Haematol Disord,2005,5 (6):441-453.

二级参考文献12

  • 1刘志福,杨光,梁英,刘蕴玲.阿托伐他汀强化治疗ACS的疗效、安全性及其对纤溶系统的影响[J].山东医药,2004,44(22):40-41. 被引量:8
  • 2吴健,陈倩.阿托伐他汀对不稳定型心绞痛患者血管内皮舒张功能的影响[J].中国动脉硬化杂志,2005,13(3):367-369. 被引量:17
  • 3Rauch U,Osende JI,Chesebro JH.Statins and cardiovascular diseases:the mutiple effects of lipid-lowing therapy by statins[J].Atherosclerosis,2000,153 (1):181-189
  • 4Frolkis JP,Pearce GL,Nambi V.Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice[J].Am J Med,2002,113 (8):625-629
  • 5Porter KE,Turner NA.Statins for the prevention of vein graft stenosis:a role for inhibition of matrix metalloproteinase-9[J].Biochem Soc Trans,2002,30 (2):120-126
  • 6Loboda A,Jazwa A,Jozkowicz A,Molema G.Angiogenic transcriptome of human microvascular endothelial cells:effect of hypoxia,modulation by atorvastatin[J].Vascul Pharmacol,2006,44 (4):206-214
  • 7Tziakas DN,Chalikias GK,Parissis JT,Hatzinikolaou EI,Tripsiannis GA,Papadopoulou EG,et al.Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes:the effects of short-term atorvastatin administration[J].Int J Cardiol,2004,94 (2):269-277
  • 8Rosenson RS,Tangney CC.Antiatherothrombotic properties of statin:implications for cardiovascular event reduction[J].JAMA,1998,279 (20):1 643-650
  • 9Cleeman JI.Executive summary of the third report of the national cholesterol education program(NCEP) expert panel on detection,and treatment of high blood cholesterol in adults (adult treatment panel)[J].JAMA,2001,285 (19):2 486-497
  • 10Schwartz GG,Olsson AG,Ezekowitz MD.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial[J].JAMA,2001,285 (13):171 1-718

共引文献14

同被引文献194

引证文献14

二级引证文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部